<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728154</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201600380 - N</org_study_id>
    <secondary_id>5R01HL132448</secondary_id>
    <nct_id>NCT02728154</nct_id>
  </id_info>
  <brief_title>The Role of Gut Microbiota in Heart Failure and Pre-Heart Failure With Preserved Ejection Fraction</brief_title>
  <official_title>Characterize the Gut Microbiota in Subjects With Heart Failure and Pre-heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gut microbiota play an important role in normal cardiovascular function and pathophysiology&#xD;
      of cardiovascular diseases. Patients with heart failure (HF) have substantial hemodynamic&#xD;
      changes which lead to intestinal hypoperfusion and congestion and eventually change gut&#xD;
      morphology, permeability, function and composition of gut microbiota and cause translocation&#xD;
      of microbial and endotoxins into the blood stream. Additionally, metabolites derived from gut&#xD;
      microbiota modulate the pathophysiology of HF. Patients with HF have intestinal overgrowth of&#xD;
      pathogenic bacteria and increased gut permeability. Accumulating evidence demonstrates that&#xD;
      antibiotic treatment benefits patients with acute coronary syndromes and reduces the&#xD;
      incidence of ischemic cardiovascular events. Taking the strong association of gut microbiota&#xD;
      with HF into account, it is reasonable to speculate that gut microbiota could contribute to&#xD;
      the progression of pre-HF with preserved ejection fraction (pre-HFpEF) to HF with preserved&#xD;
      ejection fraction (HFpEF). Pre-HFpEF remains poorly understood, yet has high prevalence and a&#xD;
      significantly high risk for death in comparison to patient without pre-HFpEF. We hypothesize&#xD;
      that altered gut microbiota is involved in the initiation and establishment of HF and&#xD;
      pre-HFpEF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research study will initially enroll 50 subjects without HF as normal controls,120&#xD;
      subjects with history of HF and 50 subjects with pre-HFpEF to characterize gut microbiota.&#xD;
      The subjects will provide blood samples and a stool sample.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stool sample for fecal microbiota between the groups</measure>
    <time_frame>Day 1</time_frame>
    <description>Stool samples will be collected to compare the fecal microbiota of subjects with normal, diastolic heart dysfunction before heart failure developed and heart failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood samples for inflammatory cytokines between the groups</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood samples will be used to compare difference in inflammatory cytokines including Interleukin-1 (IL-1), 6, 17 between groups using ELISA kits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples for SAA between the groups</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood samples will be used to compare difference in serum amyloid (SAA) a between groups using ELISA kits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples for inflammatory cells between the groups</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood samples will be used for difference in progenitor/inflammatory cells between the groups.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Normal control</arm_group_label>
    <description>The subjects in the normal heart function group will provide a blood sample and stool sample.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>heart failure</arm_group_label>
    <description>The subjects in history of heart failure group will provide a blood sample and stool sample.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pre-HFpEF</arm_group_label>
    <description>The subjects in history of diastolic dysfunction but not had heart failure clinical presentations group will provide a blood sample and stool sample.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Sample</intervention_name>
    <description>One tablespoon of blood will be drawn once during the study.</description>
    <arm_group_label>Normal control</arm_group_label>
    <arm_group_label>heart failure</arm_group_label>
    <arm_group_label>pre-HFpEF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stool Sample</intervention_name>
    <description>One stool sample will be collected.</description>
    <arm_group_label>Normal control</arm_group_label>
    <arm_group_label>heart failure</arm_group_label>
    <arm_group_label>pre-HFpEF</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and stool samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consenting participants who have normal, diastolic dysfunction or heart failure&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Competent and willing to provide consent&#xD;
&#xD;
          -  Control subjects with normal heart function&#xD;
&#xD;
          -  Subjects with history of HF&#xD;
&#xD;
          -  Subjects with impaired ventricular relaxation and/or elevated left ventricular end&#xD;
             diastolic pressure measured by echocardiography and/or catheterization, yet has not&#xD;
             had HF clinical presentations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  intestinal surgery,&#xD;
&#xD;
          -  inflammatory bowel disease,&#xD;
&#xD;
          -  celiac disease,&#xD;
&#xD;
          -  lactose intolerance,&#xD;
&#xD;
          -  chronic pancreatitis or&#xD;
&#xD;
          -  other malabsorption disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl J Pepine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana Leach, PhD</last_name>
    <phone>352-273-8944</phone>
    <email>Dana.Leach@medicine.ufl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiovascular Clinic at UF Health</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen M Handberg, PhD</last_name>
      <phone>352-273-8944</phone>
      <email>handbem@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Carl J Pepine, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanfei Qi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eileen M Handberg, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pre-clinical diastolic dysfunction (pre-HFpEF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

